David Setboun, Pharm.D., MBA

Chief Operating Officer at Alkeus Pharmaceuticals, Inc.
  • Claim this Profile
Contact Information
us****@****om
(386) 825-5501
Location
Greater Boston
Languages
  • English Native or bilingual proficiency
  • French Native or bilingual proficiency
  • Spanish Full professional proficiency
  • Portuguese Full professional proficiency
  • Italian Limited working proficiency
  • Hebrew Elementary proficiency

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

5.0

/5.0
/ Based on 2 ratings
  • (2)
  • (0)
  • (0)
  • (0)
  • (0)

Filter reviews by:

Jamie Smith

A modern-day business leader, David is approachable, pragmatic and open to new ideas. The guy has it all... a sharp business instinct, a solid track record of delivering on objectives and a courageous & collaborative leadership style that challenges and stimulates performance in others. David is a rising star who will no doubt continue to grow and become a very successful senior business executive.

Philippe Beaupere

I had the chance to meet David in University, as we were part of the same promotion. It was clear from the beginning that he was different from the average student in terms of focus and vision. He always had clear objectives in everything he did and sticked to them, without being diverted untill he reached them. Getting a sense of long term vision is an achievement in itself when you're a student and tells a lot about how strong and determined David is!

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • United States
    • Biotechnology Research
    • 1 - 100 Employee
    • Chief Operating Officer
      • May 2023 - Present

      Alkeus Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing transformative therapeutics to address serious, progressive eye diseases that lead to blindness. Our lead compound, ALK-001, is an oral investigational drug being developed for the treatment of Stargardt disease (STGD) and Geographic Atrophy (GA) secondary to dry age-related macular degeneration. ALK-001 is a selectively-deuterated form of Vitamin A that slows the dimerization of Vitamin A, which is implicated in STGD, and has shown statistically-significant and clinically-meaningful efficacy in the TEASE-1 Phase 2 clinical trial. Based on these results, ALK-001 has been granted Breakthrough Therapy Designation for the treatment of Stargardt Disease. Additional information can be found on the company’s website at www.alkeus.com. Show less

    • United States
    • Research Services
    • President
      • Oct 2018 - Present

      The Academy the world’s first global non-profit comprised of some of the best and brightest aging scientists united to accelerate breakthroughs in longevity. Our Vision We envision a world where breakthroughs in longevity are accelerated and made accessible because the most brilliant researchers, laboratories, academic institutions, regulators and drug companies are collaborating in new and innovative ways. Our Mission Our mission is accelerate the development of scientific documented interventions that will promote longer, healthier, more productive and more rewarding lives for all members of humanity. These interventions could potentially include life style alterations, nutritional modifications, pharmaceuticals, medical practice innovations and environmental improvements. Show less

    • Israel
    • Biotechnology Research
    • 1 - 100 Employee
    • Executive Vice President & Chief Operating Officer
      • Apr 2020 - May 2023
    • United States
    • Biotechnology
    • 1 - 100 Employee
    • Vice President corporate development & Strategy
      • Jul 2018 - Apr 2020
    • South Africa
    • Wellness and Fitness Services
    • 1 - 100 Employee
    • Vice President and Managing Director France at Biogen
      • Jun 2015 - Jun 2018
    • United Kingdom
    • Pharmaceutical Manufacturing
    • 700 & Above Employee
    • Country president Portugal
      • Feb 2012 - Jun 2015

    • Sales & Marketing Director Europe
      • Oct 2009 - Feb 2012

    • Global / International Brand Director, Indianapolis, USA
      • Apr 2007 - Oct 2009

Education

  • Harvard Business School
    2018 - 2018
  • Massachusetts Institute of Technology
    Leading Entreprise Transformation Program
    2013 - 2013
  • Ivey Business School at Western University
    MBA Exchange Program
    2001 - 2001
  • HEC School of Management
    MBA
    2000 - 2001
  • Université Paris Sud (Paris XI)
    Doctor of Pharmacy (Pharm.D.)
    1992 - 1998

Community

You need to have a working account to view this content. Click here to join now